Table 3.
Measles Serologic Status Before and After Measles Vaccination in P1061s
| Endpoint and Study Time Pointa | All Strata Combined | Stratum 2 | Stratum 3 | Stratum 4 |
|---|---|---|---|---|
| N | 65 | 21 | 25 | 19 |
| Percent with PRN ≥8 mIU/mL on day 0 (95% CI) | 98 (92–100) | 95 (76–100) | 100 (86–100) | 100 (82–100) |
| Percent with PRN ≥120 mIU/mL | ||||
| Day 0 (MMR administration) (95% CI) | 75 (63–85) | 71 (48–89) | 72 (51–88) | 84 (60–97) |
| Day 7 postvaccination (95% CI) | 83 (72–91) | 76 (53–92) | 88 (69–97) | 84 (60–97) |
| Day 28 postvaccination (95% CI) | 95 (87–99)b | 95 (76–100) | 92 (74–99) | 100 (82–100) |
| Percent with ≥4-fold rise in measles antibody concentration among subjects seropositive at entryc | ||||
| Day 0 to day 7 (95% CI) | 5 (1–13) | 5 (0–25) | 4 (0–20) | 5 (0–26) |
| Day 0 to day 28 (95% CI) | 25 (15–37) | 20 (6–44) | 32 (15–54) | 21 (6–46) |
| Geometric mean antibody concentration, mIU/mL (95% CI) | ||||
| Day 0 (MMR vaccination) | 295 | 238 | 316 | 342 |
| (213–409) | (122–465) | (182–547) | (196–599) | |
| Day 7 postvaccination | 407d | 338d | 379 | 550d |
| (296–561) | (172–662) | (228–631) | (314–965) | |
| Day 28 postvaccination | 834d,e | 839d,e | 812d,e | 857d,e |
| (636–1093) | (503–1401) | (486–1358) | (560–1311) |
Immunologic strata are as follows: stratum 2, pre-HAART nadir CD4 cell percentage <15% and screening CD4 cell percentage ≥15%; stratum 3, pre-HAART nadir CD4 cell percentage 15% to <25% and screening CD4 cell percentage ≥15%; stratum 4, pre-HAART nadir CD4 cell percentage ≥25% and screening CD4 cell percentage ≥25%. No statistically significant differences according to immune stratum were observed.
Abbreviations: CI, confidence interval; MMR, measles-mumps-rubella vaccine; PRN, plaque reduction neutralization antibody concentration.
a Day 7 serological results were included if they were obtained within days 5–15 after day 0 and day 28 serological results were included if they were obtained within a window of ±8 days.
b P = .02 (McNemar test) for the comparison of the proportion of subjects with measles antibody concentration ≥120 mIU/mL at day 28 vs day 7 and P ≤ .001 (McNemar test) for the comparison of the proportions of subjects with measles antibody concentration ≥120 mIU/mL at day 28 vs day 0.
c N = 64 subjects seropositive at entry, including 20 in stratum 2, 25 in stratum 3, and 19 in stratum 4.
d P ≤ .03 (paired t test) for the comparison of geometric mean antibody concentration vs the previous time point.
e P ≤ .004 (paired t test) for the comparison of geometric mean antibody concentration at day 28 vs day 0.